Clinical Trial Site

Fukuoka 830-0011

3 studies enrolling now · 7 studies all time

What they study most

AQP4+ NMOSD, Amyloidosis, Genetic Disease, High Cardiovascular Risk, High Risk Cardiovascular Disease, Hypertension, Kidney Diseases, NMOSD, Neuromyelitis Optica Spectrum Disorder, Primary Hyperoxaluria Type 1 (PH1), Primary Hyperoxaluria Type 2 (PH2), Primary Hyperoxaluria Type 3 (PH3)

Studies at this site

• TRITON-CM: A Study to Evaluate Nucresiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy — Recruiting now
• Zilebesiran in Patients With Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease — Recruiting now
• Registry of Patients With AQP4+ NMOSD Treated With Alexion C5 Inhibitor Therapies — Recruiting now
• APOLLO-B: A Study to Evaluate Patisiran in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR Amyloidosis With Cardiomyopathy) — Completed
• HELIOS-B: A Study to Evaluate Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy — Running, not enrolling
• Long Term Extension Study in Patients With Primary Hyperoxaluria — Running, not enrolling
• The Study of an Investigational Drug, Patisiran (ALN-TTR02), for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis in Participants Who Have Already Been Treated With ALN-TTR02 (Patisiran) — Completed